focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.30 (15.79%)
Spread: 0.20 (11.111%)
Open: 1.90
High: 2.20
Low: 2.20
Prev. Close: 1.90
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Jul 2014 11:35

RNS Number : 0683L
ValiRx PLC
01 July 2014
 



 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

ValiRx Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

YA Global Master SPV, Ltd

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

June 30, 2014

6. Date on which issuer notified:

June 30, 2014

7. Threshold(s) that is/are crossed orreached: vi, vii

Percentage change of greater than 1.0%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect x

Direct

Indirect

586,324,786

586,324,786

540,421,186

540,421,186

18.5%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

540,421,186

18.5%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Currently hold pursuant directly owned by YA Global Master SPV, Ltd pursuant to the SEDA and Swap Agreements totaling 540,421,186 shares of commons stock by the company.

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Steven Goldstein

15. Contact telephone number:

201-985-8300

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUAORRSVABRAR
Date   Source Headline
4th Aug 201611:32 amRNSIssue of Equity
28th Jul 20167:00 amRNSNotification of New Zealand Patent Grant Allowance
26th Jul 20167:00 amRNSIssue of Equity and Bracknor Facility Update
14th Jul 20167:00 amRNSValiSeek Clinical Development Update
12th Jul 201611:58 amRNSResult of GM
7th Jul 20167:00 amRNSSale of TRAC Technology Rights for EUR 0.8 million
27th Jun 20167:00 amRNSNotice of GM
20th Jun 20162:24 pmRNSResult of AGM
7th Jun 20167:00 amRNSQuarterly Update
7th Jun 20167:00 amRNSAppointment of Joint Broker
26th May 20168:00 amRNSPosting of Annual Report & Notice of AGM
19th May 201611:00 amRNSFinal Results
19th May 20167:00 amRNSValiSeek Clinical Development Update
18th May 20164:45 pmRNSConversion of Loan Note, issue of warrant & equity
29th Apr 20167:00 amRNSNotification of US Patent Grant for VAL401
26th Apr 201612:07 pmRNSIssue of Equity
22nd Apr 201610:01 amRNSValiRx to exhibit at the UK Investor Show
19th Apr 20163:32 pmRNSIssue of Equity - conversion of loan note
18th Apr 20165:00 pmRNSIssue of Equity - conversion of loan note
1st Apr 20163:10 pmRNSConversion of Loan Note, issue of warrant & equity
31st Mar 20167:00 amRNSValiRx to exhibit and present at the AACR
21st Mar 20167:00 amRNSConvertible Loan Facility of up to £4.0 million
17th Mar 20167:00 amRNSValiRx engages US investor relations firm
17th Feb 20161:00 pmRNSPlacing to raise £0.5 million
16th Feb 20167:00 amRNSVAL201 Clinical Trial Update
9th Feb 20167:00 amRNSQuarterly Update on Clinical Progress
11th Dec 20159:30 amRNSValiRx to present at Shares Investor Meeting
19th Nov 201510:45 amRNSClinical Phase Development Update
5th Nov 20157:00 amRNSValiRx establishes US office in Boston, MA
27th Oct 20157:00 amRNSCollaboration Agreement
1st Oct 20157:00 amRNSNew Japanese Patent Grant
17th Sep 201512:15 pmRNSHalf Yearly Report
16th Sep 20157:00 amRNSSubscription and Equity Swap
6th Aug 20157:00 amRNSCollaboration and Research Studentship Agreement
21st Jul 20157:00 amRNSVAL201 Clinical Trial Update
16th Jul 20157:00 amRNSValiSeek Clinical Development Update
29th Jun 20157:00 amRNSGrant of options
25th Jun 20157:00 amRNSUPDATE on VAL201 Clinical Trial
3rd Jun 20157:00 amRNSChange of Adviser
27th May 201511:22 amRNSStmnt re Share Price Movement
15th May 20152:45 pmRNSResult of AGM and Capital Reorganisation
14th May 20153:50 pmRNSNotification of US Patent Grant Allowance reVAL401
14th May 20157:00 amRNSValiSeek Development Update
7th May 20157:00 amRNSRe Contract
30th Apr 20157:00 amRNSValiRX to attend 2015 BIO International Convention
22nd Apr 20157:00 amRNSNotice of AGM and Proposed Capital Reorganisation
16th Apr 20157:00 amRNSFinal Results
17th Mar 20157:00 amRNSIssue of equity to Cancer Research Technology Ltd
6th Mar 20157:00 amRNSPlacing to raise GBP800,000
26th Feb 20157:00 amRNSNew Endometriosis Patent Grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.